FMC Corp vs Intuitive Surgical, Inc. — how do they compare? FMC Corp trades at $11.45 (market cap $1.36B), while Intuitive Surgical, Inc. trades at $400.14 (market cap $137.76B). The key difference: Intuitive Surgical, Inc. is far larger — about 101.3× FMC Corp's market cap, and FMC Corp pays a 2.95% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals.
| FMC | ISRG | |
|---|---|---|
Market Cap | $1.36B | $137.76B |
Sector | Basic Materials | Health |
52-Week High | $43.90 | $592.85 |
52-Week Low | $10.72 | $379.50 |
Enterprise Value | $5.50B | $133.24B |
Dividend Yield | 2.95% | — |
Signals from Pluang's Aura AI — not financial advice
FMC Corporation (FMC) trades at $10.72, down 1.74% on the day, reflecting ongoing challenges despite recent strategic moves. The stock shows a bearish technical trend with oversold RSI signals, while fundamentals reveal significant pressure with a net income margin of -72.93% and negative ROE of -80.78% for 2025. Recent developments include a $400 million minority investment from Tessenderlo Group and regulatory submission for new herbicide rimisoxafen, providing some operational support amid financial restructuring.
The outlook remains cautious with analyst consensus leaning neutral (50% Hold) despite a $16 price target suggesting 49% upside. Key risks include persistent revenue declines, high debt levels, and negative cash flow from operations. Investment opportunity exists if new product approvals and debt reduction efforts successfully stabilize profitability, but current financial metrics indicate substantial execution risk near term.
Intuitive Surgical (ISRG) trades at $379.50, down 6.78% amid broader market pressure, yet maintains strong fundamentals with 28.15% net margins and consistent earnings beats. The stock faces technical headwinds with bearish moving averages but shows oversold RSI conditions. Recent news highlights competitive pressures but also strong da Vinci 5 adoption and upcoming Q2 earnings on July 16, where analysts expect another beat. Revenue growth remains robust at $10.06B for 2025, up from $8.4B in 2024.
Despite near-term volatility, ISRG's leadership in robotic surgery and analyst consensus price target of $552.36 suggest significant upside. Key risks include intensifying global competition and margin pressures, but the company's innovation pipeline and expanding procedure volumes support long-term growth. Institutional sentiment remains positive with 69.6% buy ratings, positioning ISRG as a compelling recovery candidate post-earnings.
Trailing returns across standard periods
Latest headlines on both assets
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →